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Abstract
Background: Microarray techniques have revolutionized genomic research by making it possible
to monitor the expression of thousands of genes in parallel. As the amount of microarray data being
produced is increasing at an exponential rate, there is a great demand for efficient and effective
expression data analysis tools. Comparison of gene expression profiles of patients against those of
normal counterpart people will enhance our understanding of a disease and identify leads for
therapeutic intervention.
Results: In this paper, we propose an innovative approach, fuzzy membership test (FM-test), based
on fuzzy set theory to identify disease associated genes from microarray gene expression profiles.
A new concept of FM d-value is defined to quantify the divergence of two sets of values. We further
analyze the asymptotic property of FM-test, and then establish the relationship between FM d-value
and p-value. We applied FM-test to a diabetes expression dataset and a lung cancer expression
dataset, respectively. Within the 10 significant genes identified in diabetes dataset, six of them have
been confirmed to be associated with diabetes in the literature and one has been suggested by
other researchers. Within the 10 significantly overexpressed genes identified in lung cancer data,
most (eight) of them have been confirmed by the literatures which are related to the lung cancer.
Conclusion: Our experiments on synthetic datasets show that FM-test is effective and robust.
The results in diabetes and lung cancer datasets validated the effectiveness of FM-test. FM-test is
implemented as a Web-based application and is available for free at http://database.cs.wayne.edu/
bioinformatics.
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Background
Microarray techniques have revolutionized genomic
research by making it possible to monitor the expression
of thousands of genes in parallel. As the amount of microarray data being produced is increasing at an exponential
rate, there is a great demand for efficient and effective
expression data analysis tools. The gene expression profile
of a cell determines its phenotype and responses to the
environment. These responses include its responses
towards environmental factors, drugs and therapies. Gene
expression patterns can be determined by measuring the
quantity of the end product, protein, or the mRNA template used to synthesize the protein. Comparison of gene
expression profiles in patients against their normal counterpart people will enhance our understanding of a disease and identify leads for therapeutic intervention.
Several important breakthroughs and progress in the gene
expression profiling of diseases have been made [1-5].
More interestingly, researchers have identified many
genes that play important roles in the onset, development,
and progression of various diseases. Identification of
these disease genes offers a route to a better understanding
of the molecular mechanisms underlying pathogenesis, a
necessary prerequisite for the rational development of
improved preventative and therapeutic methods.
One effective approach of identifying genes that are associated with a disease is to measure the divergence of two
sets of values of gene expression. A motivating example is
shown in Table 1, which records the microarray gene
expression values of five genes for two groups of people
that are related to diabetes [6]: five insulin-sensitive (IS)
humans and five insulin-resistant (IR) humans. In order
to identify the genes that are associated with diabetes, one
needs to determine for each gene whether or not the two
sets of expression values are significantly different from
each other. The two most popular methods to measure
the divergence of two sets of values are t-test [7] and Wilcoxon rank sum test [7], The statistical method t-test
assesses whether the means of two groups are statistically

different from each other. Given two sets S1 and S2, the tvalue is calculated as

t(S1 , S2 ) =

μS1 − μS2
σ2S

1

S1

+

(1)

σ2S

2

S2

where μS and σS are the sample mean and standard deviation of S, respectively.
The limitation of t-test is that it cannot distinguish two
sets with close means even though the two sets are significantly different from each other. Another limitation of ttest is that it is very sensitive to extreme values.
Another popular statistical method is Wilcoxon rank sum
test, which can be used to test the null hypothesis that two
sets S1 and S2 have the same distribution. We first merge
the data from these two sets and rank the values from the
lowest to the highest with all sequences of ties being
assigned an average rank. The Wilcoxon test statistic W is
the sum of the ranks from set S1. Assuming that the two
sets have the same continuous distribution (and no ties
occur), then W has a mean and standard deviation given
by

μ=

σ=

m *(m + n + 1)
2

(2)

m * n *(m + n + 1)
12

(3)

where m = |S1| and n = |S2|.
We test the null hypothesis Ho: no difference in distributions. A one-sided alternative is Ha: S1 yields lower measurements. We use this alternative if we expect or see that
W is unusually lower than its expected value μ. In this
case, the p-value is given by a normal approximation. We

Table 1: The gene expression values for five genes under two conditions.

Gene ID

IR

IS

d-value

p-value
FM

1
2
3
4
5

750
123
246
200
598

559
142
213
191
424

649
11
232
220
695

685
406
134
83
451

636
220
67
197
141

310
305
86
49
342

359
398
79
81
260

135
707
77
116
266

97
905
94
111
229

178
688
61
135
234

0.999
0.756
0.725
0.708
0.674

0.001
0.012
0.017
0.019
0.025

t-test
0.008
0.011
0.021
0.024
0.077

rank sum
0.000
0.031
0.098
0.058
0.152

Five sample genes contain two set of gene expression for two groups of people: five insulin-sensitive humans (IS) and five insulin-resistant (IR)
humans. Each set of gene expression contains five gene expression values. Four values are calculated for each gene: d-value, p-value for FM-test, pvalue for t-test, and p-value for rank sum test.
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let N~N(μ,σ) and compute the left-tail Pr(N ≤ W) (using
continuity correction if W is an integer).

2. We calculated the d-value for each pair of sets.
3. We then estimated the probability density value

If we expect or see that W is much higher than its expected
value, then we should use the alternative Ha: first S1 yields
higher measurements. In this case, the p-value is given by
the right-tail Pr(N ≥ W). If the two sums of ranks from
each set are close, then we could use a two-sided alternative Ha: there is a difference in distributions. In this case,
the p-value is given by twice the smallest tail value 2*Pr(N
≤ W), if W < μ; or 2*Pr(N ≥ W), if W > μ.
Although rank sum test overcomes the limitation of t-test
in sensitivity to extreme values, it is not sensitive to absolute values. This might be advantageous to some applications but not to others.

Results
To validate our approach, first, we investigated the distribution of FM d-value on a set of synthetic datasets. Second, we conducted experiments on a synthetic dataset to
study the relationship between FM-test d-value and its
empirical p-value. Third, on another synthetic dataset, we
studied the relationship between FM d-value and the
mean difference of distributions.
The probability distribution of FM d-value
Suppose two sets S1 and S2 are randomly drawn from the
same normal distribution, what is the probability distribution of FM d-value? To answer this question, we conducted the following simulation:

1. We generated N = 64000 pairs of sets of values, with
each set containing 5 values. As shown in Figure 1(a),
each value in the two data sets is randomly generated from
the same normal distribution N(0,1).

Figure 1generation of d-value from normal distribution
Random
Random generation of d-value from normal distribution. (a) shows the random generation of two sets of values
from the same normal distribution and the calculation of the
FM d-value of these two sets. (b) shows the random generation of two sets of values from two different normal distributions and the calculation of FM d-value of these two sets.

|{i | d − δ < di ≤ d + δ}|
where δ = 0.005. The value
N * 2δ
is essentially the fraction of the FM d-values falling in
region [d-δ, d+δ] divided by the region length 2δ. The
probability density function of the d-distribution was
drawn in Figure 2.
f (d) =

4. At the end, in order to understand the effect of the
number of pairs used for simulation, i.e., the size of the
dataset, on the approximation error of the d-distribution,
we generated datasets with different data sizes. For each
data size, we generated 10 datasets, and thus derived 10
probability density functions. The maximum standard
deviation for all d-values is recorded as the error rate for
that data size. As shown in Figure 3, as expected, the error
rate decreases as the size of the dataset increases.
From Figure 2, we can see that most FM d-values fall into
the range from 0.2 to 0.5, and very few fall into the range
greater than 0.6, or less than 0.2. In particular, when d ≥
0.6056, p-value ≤ 0.05. This is reflected in the red-shared
area in Figure 2 with

1.0

∫0.6056

f(x)dx = 0.05. Therefore,

given two sets S1 and S2 drawn from the same normal unit
distribution, the chance that the pair has a FM d-value
equal to or greater than 0.6056 is very low. On the other
hand, if we observe that two sets have a d-value equal to
or greater than 0.6056, then this is strong evidence that
these two sets are drawn from two different distributions.

Figure
The
probability
2
density function of FM d-value
The probability density function of FM d-value. The
probability density function of FM d-value shows that most dvalues falls into the middle region and only 5% d-values are
greater than 0.6058; these d-values are considered significant.
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4. We drew the relationship between d-value and empirical p-value in Figure 4.
From Figure 4, we can see that as d-value increases, the pvalue decreases. In particular, when d ≥ 0.6056, we have
p-value ≤ 0.05.
Relationship between FM d-value and the mean difference
of distributions
Suppose two sets S1 and S2 are drawn from two different
distributions, then a good divergence measurement
should satisfy the following property: the less overlap
between these two distributions, the greater the d-value.
We validated that our FM-test has this property as follows:

valueimpact
The
Figure
3 of dataset size on error rate of PDF of FM dThe impact of dataset size on error rate of PDF of
FM d-value. We show the error rate for different data sizes
from 500 to 32000. For each data size, we generated 10
datasets, and thus derived 10 probability density functions.
The maximum standard deviation for all d-values is recorded
as the error rate for that data size. The error rate decreases
as the size of the dataset increases.
Therefore, they should be considered as significantly
divergent.
Figure 3 shows the effect of data size on the error rate of
the derived probability density function. As the data size
increases, the error rate decreases. We can see from Figure
3 that, after the number of pairs of sets in a dataset is
greater than 8000, the trend of the error rate becomes stable. Thus, to obtain a reliable empirical p-value for FMtest, the data size should be greater than 8000.

1. As shown in Figure 1(b), two data sets are generated
from two distributions. Let N(0,1) and N(x, 1) be two
normal distributions, where x is the mean difference
between these two distributions. In this experiment, we
consider x = 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, respectively.
2. We generated 1000 pairs of sets of values, with the first
set containing 5 values that are randomly generated from
N(0,1), and the second set containing 5 values that are
randomly generated from N(x, 1).
3. We calculated the d-value for each pair. Let the average
of these 1000 d-values be d. We then plotted (x, d) in Figure 5.
4. We repeated step 2 and 3 for different x. Finally, the
curve was drawn in Figure 5.

Relationship between FM d-value and its empirical p-value
Suppose two sets S1 and S2 are drawn from the same normal distribution, what is the probability that they have a
FM d-value equal to or greater than a particular D? If the
D increases, will this probability decrease? To answer
these questions, we studied the relationship between FM
d-value and empirical p-value as follows:

1. Based on the above experimental result, we know that
we need at least 8000 pairs of sets to obtain a reliable
empirical p-value. Therefore, in this experiment, we generated 10000 pairs of sets of values, with each set containing 5 values. Each value is randomly generated from the
unit normal distribution N(0,1).
2. We calculated the d-value for each pair of sets.
3. For each pair of sets S1 and S2 with d-value D, we calculated its empirical p-value as n+1/10001 where n is the
number of pairs in these 10000 pairs that have a d-value
equal to or greater than D.

valuerelationship
The
Figure
4
between FM d-value and its empirical pThe relationship between FM d-value and its empirical p-value. It shows the relationship between d-value and
its empirical p-value. We can see that as d-value increases,
the p-value decreases. In particular, when d ≥ 0.6056, we
have p-value ≤ 0.05.
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Figure
Relationship
and
d-value
5 between the mean difference of distributions
Relationship between the mean difference of distributions and d-value. Two datasets are generated from
two distributions. Let N(0,1) and N(x, 1) be two normal distributions, where x is the mean difference between these
two distributions. In this experiment, we consider x = 0, 0.5,
1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, respectively. The d-value between
two sets increases when the mean difference of two data
sets increases.

Figure 5 confirmed the desirable property of FM-test: the
larger the mean difference between the two distributions,
the greater the d-value.

To study the relevance of genes in insulin metabolism and
diabetes, the 10 best ranked differentially regulated genes
shown in Table 2 were further searched in the published
literature. Human phosphatidylinositol(4,5) bisphosphate 5-phosphatase homolog (gene U45973) was found
to be differentially expressed in insulin resistance cases.
Over-expression of inositol polyphosphate 5-phosphatase-2 SHIP2 has been shown to inhibit insulin-stimulated phosphoinositide 3-kinase (PI3K) dependent
signaling events. Analysis of diabetic human subjects has
revealed an association between SHIP2 gene polymorphism and type 2 diabetes mellitus. Also knockout mouse
studies have shown that SHIP2 is a significant therapeutic
target for the treatment of type-2 diabetes as well as obesity [8]. Csermely et al. reported that insulin mediates
phosphorylation/dephosphorylation of nucleolar protein
nucleolin (gene M60858) by stimulating casein kinase II,
and this may play a role in the simultaneous enhancement in RNA efflux from isolated, intact cell nucle [9]. cmyc is an oncogene that codes for transcription factor Myc
that along with other binding partners such as MAX plays
an important role widely studied in various physiological
processes including tumor growth in different cancers.
Myc modulates the expression of hepatic genes and counteracts the obesity and insulin resistance induced by a
high-fat diet in transgenic mice overexpressing c-myc in
liver [10].

Analyzing diabetes data with FM-test
A diabetes dataset of microarray gene expression for a
total of 10831 genes downloadable from [6] is used for
analysis. For each gene, there are ten expression values,
five from a group of insulin-sensitive (IS) people and five
from a group of insulin-resistant (IR) people. Only the
genes that have no null expression values are included in
this analysis. We also require that, for a gene to be
included, at least five out of its ten expression values are
greater than 100. This eliminates the genes whose expression values are noisy and not reliable.

Max interactor protein, MXI1 (gene L07648) competes for
MAX thus negatively regulates MYC function and may
play a role in insulin resistance. In the presence of glucose
or glucose and insulin, leucine is utilized more efficiently
as a precursor for lipid biosynthesis by adipose tissue. It
has been shown that during the differentiation of 3T3-L1
fibroblasts to adipocytes, the rate of lipid biosynthesis
from leucine increases at least 30-fold and the specific
activity of 3-hydroxy-3-methylglutaryl-CoA lyase (gene
L07033), the mitochondrial enzyme catalyzing the terminal reaction in the leucine degradation pathway, increases
4-fold during differentiation [11]. Schottelndreier et
al[12] have described a regulatory role of integrin alpha 6
(gene X53586) in Ca2+ signaling, that is known to have a
significant role in insulin resistance [13].

The results of FM-test are compared with the results of ttest and rank sum test. As we can seen in Table 2 although
the orders of ranking are different for different methods,
all three methods identify these genes as significantly differentially expressed between the IS and IR groups. Furthermore, 10 worst ranked genes in FM-test shown in
Table 2 are also consistent with the result of the other two
methods. However, gene U49835 is identified by FM-test
as the 21st ranked significant gene with p-value 0.0258.
Neither t-test (with p-value 0.0768) nor rank sum test
(with a p-value 0.1522) identifies this gene as significant.

HCGV gene product (gene X81003) is known to inhibit
the activity of protein phosphatase-1, which is involved in
diverse signalling pathways including insulin signaling
[14]. Human ribosomal protein L7 (Gene X57959)plays a
regulatory role in eukaryotic translation apparatus. It has
been shown to be an autoantigen in patients with systemic autoimmune diseases, such as systemic lupus erythematosus [15]. Identification of this gene in our
analysis and by [6] suggests a possible role of this gene in
insulin resistance. Published reports on these genes indicate their roles in insulin signalling and warrant further

Discussion
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Table 2: Ten best-ranked and worst-ranked genes of diabetes identified by FM-test.
Probe Set

Gene Description

d-value

Empirical p-value

t-test p-value

rank sum p-value

U45973
M60858
D85181
M95610
L07648
L07033
X53586
X81003
X57959
U06452

Human phosphatidylinositol (4,5) bisphosphate
Human nucleolin gene
Homo sapiens mRNA for fungal sterol-C5-desaturase homolog
Human alpha 2 type IX collagen (COL9A2) mRNA
Human MXI1 mRNA
Human hydroxymethylglutaryl-CoA lyase mRNA
Human mRNA for integrin alpha 6
Homo sapiens HCG V mRNA
ribosomal protein L7
melan-A

0.999
0.935
0.892
0.872
0.858
0.855
0.851
0.791
0.767
0.756

0.0003
0.0016
0.0028
0.0038
0.0043
0.0046
0.0047
0.0089
0.0108
0.0126

0.0001
0.0017
0.0029
0.0066
0.0052
0.0054
0.0075
0.0077
0.0109
0.0118

0.0076
0.0076
0.0147
0.0076
0.0076
0.0076
0.0076
0.0076
0.0313
0.0311

X82324
M14764
M64673
U20657
D17793
D78014
AB002314
L20348
D50063
Z79581

POU domain, class 3, transcription factor 4
nerve growth factor receptor (TNFR superfamily, member 16)
heat shock transcription factor 1
ubiquitin specific peptidase 4 (proto-oncogene)
aldo-keto reductase family 1, member C3
dihydropyrimidinase-like 3
PDZ domain containing 10
oncomodulin
proteasome (prosome, macropain) 26S subunit
H.sapiens LAZ3/BCL6 gene, first non coding exon

0.206
0.204
0.204
0.197
0.196
0.194
0.191
0.181
0.179
0.179

0.9987
0.9989
0.9990
0.9993
0.9999
1
1
1
1
1

0.407
0.652
0.652
0.642
0.471
0.620
0.367
0.405
0.544
0.545

1
1
0.844
0.844
0.839
0.548
0.545
0.544
0.421
0.407

investigations on their functions in insulin resistance
cases. We further recommend genes D85181, M95610 and
U06452 as candidate genes for future research in this area.
In order to compare the fold change of expression levels
between the IS and IR groups to the statistical significance
p-values, we presented all the genes in the diabetes dataset
with a volcano plot shown in Figure 6. The volcano plot
arranges the genes along dimensions of biological and statistical significance. The X axis is the fold change between
the two groups, which is on a log scale log2( IS / IR ),
where IS is the mean of expressions in the IS group, and

IR is the mean of the expressions in the IR group. In this
way, up and down regulation appear symmetric. The Y
axis represents the p-value for our FM-test, which is on a
negative log scale log10(p-value), so that smaller p-values
appear higher up. The X axis indicates biological impact of
the change; the Y axis indicates the statistical evidence, or
reliability of the change.
As shown in Figure 6, gene U45973 is identified by FMtest as the most statistically significant gene and it is overexpressed in the IR group; gene X53586 is identified by
FM-test as the 7th statistically significant gene and it is
over-expressed in the IS group. Although genes M60858,
D85181, M95610, L07648, L07033, and X81003 have
been identified by FM-test among the top ten significant
genes, they are not over-expressed in either groups.
Finally, gene U41515 is identified by FM-test as the 11th
significant gene and it is over-expressed in the IS group.

In summary, out of the top 10 genes identified by FM-test,
we could find 6 of them in the literature about their association with insulin metabolism and diabetes. Among the
remaining four genes, gene X57959 has been recommended by [6] as a candidate gene for diabetes, we recommend that gene D85181, M95610 and U06452 could
serve as candidate genes for future research in this area.
Analyzing lung cancer data with FM-test
To study the relevance of significant genes in lung cancer,
a dataset of microarray gene expression for a total of
22283 genes downloadable from [16] is used for analysis,
the top ranked genes were further searched in the published literature. Most of the genes we found have a validated role in tumor progression. As showed in Table 3, we
discuss a few genes that we ranked best using our method.
Multiple identifiers of Keratins were ranked significant in
the dataset. Cytokeratins are a polygenic family of insoluble proteins and have been proposed as potentially useful
markers of differentiation in various malignancies including lung cancers [17]. Dystonin (DST/BPAG1) is a member of plakin protein family of adhesion junction plaque
proteins. A recent study showed the expression of
BPAG1in epithelial tumor cells [18]. Maspin (SERPINB5)
was has been shown to be involved in both tumor growth
and metastasis such as cell invasion, angiogenesis, and
more recently apoptosis [19]. Tumor protein p73-like
(TP73L/P63) is implicated in the activation of cell survival
and antiapoptotic genes [20] and has been used as a
marker for lung cancer. It has been suggested that the p63
genomic amplification has an early role in lung tumorigenesis [21]. CLCA2 belongs to calcium sensitive chloride
conductance protein family and has been used in a multi-
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membrane DSP in Squamous Cell Carcinomas (SCC)
[24]. The data analysis also identified cell cycle regulatory
proteins such as CDC20 and Cyclin B1. Overexpression of
CDC20 has been shown to be associated with premature
anaphase promotion, resulting in mitotic abnormalities
in oral SCC cell lines [25]. Mini chromosome
maintenance2 (MCM2) protein is involved in the initiation of DNA replication and is marker for proliferating
cells [26]. Our analysis also identified GPR87
(NM_023915) and UGT1A9 (NM_019093). Role of G
protein coupled receptors are well documented in lung
cancer and GPR87 could be an important gene in cancer
progression. Among overexpressed genes, we suggest
NM_023915 and NM_019093 as potential candidates for
biological investigation.

Conclusion
Figure
The
volcano
6 plot for the diabetes dataset
The volcano plot for the diabetes dataset. We compare the fold change of expression levels between the IS and
IR groups to the statistical significance p-values in a volcano
plot. The volcano plot arranges the genes along dimensions
of biological and statistical significance. The X axis is the fold
change between the two groups, which is on a log scale
log2( IS / IR ), where IS is the mean of expressions in the IS
group, and IR is the mean of the expressions in the IR
group. As we can see, a few genes shows significant difference can be visualized in the plot.

gene detection assay for Non Small Cell Lung Cancer
(NSCLC) [22]. Plakophilins (PKPs) are members of the
armadillo multigene family that function in cell adhesion
and signal transduction, and also play a central role in
tumorigenesis [23]. Desmoplakin (DSP) is a desmosome
protein that anchors intermediate filaments to desmosomal plaques. Microscopic analysis with fluorescencelabeled antibodies for DSP revealed high expression of

We proposed an innovative approach based on the fuzzy
set theory, FM-test, that quantifies the divergence of two
sets directly. We have validated FM-test on synthetic datasets and show that it is effective and robust. We also
applied FM-test to a real diabetes dataset and a cancer
dataset. For each dataset, we identified 10 significant
genes. Within 10 significant genes in diabetes dataset, six
of them have been confirmed to be associated with insulin signalling and/or diabetes in the literature, one has
been recommended by others, the remaining three genes,
D85181, M95610 and U06452, are suggested as three
potential diabetes genes involved in insulin resistance for
further biological investigation. Out of the 10 significantly overexpressed genes identified in the lung cancer
data eight are confirmed by literature to be related to lung
cancer. The remaining two genes NM_023915 and
NM_019093 are potential candidates for further biological investigation. In addition, we analyzed the asymptotic
properties of the distribution of FM d-value and the equation to calculate its p-value. The analysis is presented in
appendix. FM-test is implemented as a Web-based application and can be accessed for free at http://data
base.cs.wayne.edu/bioinformatics.

Table 3: Ten best-ranked (overexpressed) cancer genes identified by FM-test.

Probe Set
NM_173086
NM_001723
NM_002639
AB010153
NM_023915
NM_006536
NM_001005337
AF043977
NM_004415
NM_019093

Gene Description

p-value

KRT6E: Keratin 6E
DST: Dystonin
SERPINB5: Serpin peptidase inhibitor, clade B (ovalbumin), member 5
TP73L: Tumor protein p73-like
GPR87: G protein-coupled receptor 87
CLCA2: Chloride channel, calcium activated, family member 2
PKP1: Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)
CLCA2: Chloride channel, calcium activated, family member 2
DSP: Desmoplakin
UGT1A9: UDP glucuronosyltransferase 1 family, polypeptide A9

0.000125
0.000125
0.000125
0.000125
0.000125
0.000125
0.000125
0.000125
0.000125
0.000125
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Methods
In this section, based on the fuzzy set theory [27], we
present our innovative approach, the fuzzy-set-theorybased method test (FM-test), to quantify the divergence of
two sets of values directly and robustly. In addition, in
append ix section, we show the asymptotic property of
FM-test, and then establish the relationship between FM
d-value with p-value.
Let S1 and S2 be two sets of values of a particular feature for
two groups of samples under two different conditions.
The basic idea is to consider the two sets of values as samples from two different fuzzy sets. We examine the membership value of each element with respect to the other
fuzzy set. By calculating the average of membership values, we measure the divergence of the original two sets. In
particular, we perform the following steps:
1. Compute the sample mean and standard deviation of
S1 and of S2 respectively.
2. Characterize S1 and S2 as two fuzzy sets FS1 and FS2
whose fuzzy membership functions, fFS1 (x) and fFS2 (x),
are defined with the sample means and standard deviations. The fuzzy membership function fFSi (x)(i = 1,2)
maps each value x to a fuzzy membership value that
reflects the degree of x belonging to fFSi (x)(i = 1,2).
3. Using the two fuzzy membership functions, fFS1 (x)
and fFS2 (x), quantify the convergence degree of two sets.
4. Define the divergence degree (FM d-value) between the
two sets based on the convergence degree.

2

fFS1 ( x) = e −( x −μ1 )

/ 2σ12

(6)

The function fFS1 (x) maps each value x in S1 to a fuzzy
membership value to quantify the degree that x belongs to
FS1. A value equal to the mean has a membership value of
1 and belongs to fuzzy set FS1 to a full degree; a value that
deviates from the mean has a smaller membership value
and belongs to FS1 to a smaller degree. The further the
value deviates from the mean, the smaller the fuzzy membership value. Similarly, the fuzzy membership function
for S2 is defined as
2

fFS2 ( x) = e −( x −μ2 )

/ 2σ22

(7)

where μ2 and σ2 are the mean and standard deviation of S2
respectively.
For

gene

5

in

Table

2

/ 88696.3

2

/ 4102.4

fFS1 ( x) = e −( x −461.8)

fFS2 ( x) = e −( x −266.2)

1,

we

have
and

. With these two fuzzy mem-

bership functions, the fuzzy membership values for each
element with respect to the two sets can be calculated. For
example, fFS1 (598) = 0.81 and fFS2 (598) = 2.2E-12.
Our Proposed Method: FM-test
Since the fuzzy membership functions can overlap, one
element can belong to more than one fuzzy set with a
respective degree for each. For an element in S1, we meas-

ure the degree that it belongs to FS1 by applying its value
to fFS1 . Similarly we can apply its value to fFS2 to meas-

Fuzzy Sets and Membership Functions
The sample mean μ1 of S1 is calculated as

μ1 =

1
n1

∑

xi ∈S1

xi

with respect to S2 as a bond between S1 and S2, and vice

(4)

where n1 is the number of elements in S1, and the sample
standard deviation σ1 of S1 is calculated as
σ1 =

1
2
∑ ( xi −μ1 )
n1 −1 xi ∈S1

ure the degree that it belongs to FS2. The idea of FM-test is
to consider the membership value of an element in S1

(5)

For gene 5 in Table 1, we have μ1 = 461.8, σ1 = 210.59, μ2
= 266.2, and σ2 = 45.29. We then characterize set S1 by a
fuzzy set FS1 whose fuzzy membership function is defined
as

versa, then the aggregation of all these bonds reflects the
overall bond between these two sets. The weaker this overall bond is, the more divergent these two sets are. The
strength of the overall bond between two sets is quantified
by their c-value, which aggregates the mutual membership
values of elements in S1 and S2 and is defined as follows.
Definition 1 (FM c-value): Given two sets S1 and S2, the
convergence degree between S1 and S2 in FM-test is
defined as

Page 8 of 13
(page number not for citation purposes)

BMC Bioinformatics 2006, 7(Suppl 4):S7

∑

c(S1 , S2 ) =

e∈S1

fF(S2 )(e) +

∑

f ∈S2

ical p-value as (n+1)/(N+1), where n is the number of
pairs whose FM d-values are equal or greater than D.

fF(S1 )( f )
(8)

S1 + S2

Now we define the divergence value in FM-test (FM dvalue) as follows.
Definition 2 (FM d-value): Given two sets S1 and S2, the
FM d-value between S1 and S2 is defined as

∑

d(S1 , S2 ) = 1 − c(S1 , S2 ) = 1 −

e∈S1

fF(S2 )(e) +

∑

f ∈S2

S1 + S2

Authors' contributions
LRL and SL designed the algorithm and coordinated the
project. XW proved the asymptotic property of FM-test
and wrote part of manuscript. YL carried out the study and
drafted the manuscript. VM implemented the Web-based
application of FM-test. DP and DK analyzed gene functional data and wrote part of manuscript.

APPENDIX

fF(S1 )( f )
(9)

For gene 5 in Table 1, c(S1, S2) = 0.326, thus the divergence value is 1-c(S1, S2) = 0.674. We calculated all the pvalues for the five genes in Table 1 for the three methods.
One interesting observation is that, while both t-test and
Wilcoxon rank sum test fail to recognize gene 5 as a significant gene since their p-values are greater than 0.05, our
FM-test identifies gene 5 as a significant gene with a pvalue of 0.025. The reason of the failure of t-test and Wilcoxon rank sum test is due to their sensitivity to the
extreme value 141 in the first set of the gene.

Asymptotic Characteristics of the FM d-value
The FM d-value is defined in Method section as follows:

∑

d(S1 , S2 ) = 1 − c(S1 , S2 ) = 1 −

We perform the following steps to calculate the p-value of
two sets S1 and S2 with their FM d-value D: (1) Estimate
the distribution that S1 and S2 are drawn from a normal
distribution N(μ,σ), where μ and σ are estimated using
the sample mean and standard deviation of S1 ∪ S2; (2)
Randomly draw N pairs of sets from N(μ,σ), then calculate the FM d-value for each pair; (3) Calculate the empir-

fF(S2 )(e) +

∑

f ∈S2

fF(S1 )( f )
.

S1 + S2

(10)

Here we are trying to establish the asymptotic characteristics of the FM d-value by estimating its corresponding
mean and variance. To the end, formula (10) is rewritten
by defining an indicator variable ISi (·) as follows:
n1 + n2

Given a calculated FM d-value D for two sets S1 and S2, to
interpret D in terms of "significantly divergent" or not, we
need to know the cutoff value δ of D, so that when D ≥ δ,
the two sets are interpreted as significantly divergent. In
the context of FM-test, we like to test the following null
hypothesis Ho: S1 and S2 originate from the same distribution. Then the p-value is defined as the probability
{Pr(d(S1, S2) ≥ D | S1 and S2 were randomly sampled from
the same distribution}. As a convention of statistical analysis, if p-value ≤ 0.05, then this is strong evidence to reject
the null hypothesis, and accepts that the two sets are significantly divergent, while the p-value reflects the significance. It has been very common to use Monte Carlo
procedures to calculate the empirical p-value which
approximates the exact p-value without relying on asymptotic distributional theory or on exhaustive enumeration.
Davison and Hinkley [28] present the formula for obtaining an empirical p-value as (n+1)/(N+1), where N is the
number of samples in the data set, and n is the number of
those samples which produce the statistical value greater
than or equal to the specified value.

e∈S1

∑

d(S1 , S2 ) = 1 − c(S1 , S2 ) = 1 − i =1

(IS1 ( xi ) fF(S2 )( xi ) + IS2 ( xi ) fF(S1 )( xi ))
,

n1 + n2

(11)

where S = S1∪ S2 = {xi,i = 1,..., n1 + n2}, n1 = |S1| · n2 = |S2|
and ISi (x) = 1 if x ∈ Si and 0 otherwise for i = 1,2.
Let Δ( X ) = IS1 ( X ) fF(S2 )( X ) + IS2 ( X ) fF(S1 )( X ) w.r.t. a r.v. X
over sample space S with a probability p of choosing a
sample x from S1. The calculation of the d-value for a
given sample x is therefore given by d(S1,S2) = = 1 - Δ( x) .
Next, the mean and the variance of Δ(X) are calculated
respectively preparing for establishing the asymptotic distribution of the d-value.
(1). Calculation of the mean of Δ(X)
The mean of Δ(X) is given by
E(IS1 ( X) fF(S2 )( X) + IS2 ( X) fF(S1 )( X))
2

= E(e −( X −μ2 )
= pE(e

/ 2σ22

2

| S1 )P(S1 ) + E(e −( X −μ1 )

−( X −μ2 )2 / 2σ22

| S1 ) + (1 − p)E(e

/ 2σ12

| S2 )P(S2 )

−( X −μ1 )2 / 2σ12

( 12 )

| S2 )
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Therefore, when p = 0.5
2

E(e −( X −μ2 )

/ 2σ22

∫e

| S1 ) =

2

−( X −μ2 )

2
2
⎡ 1
e −( X −μ1 ) / 2σ1
⎢
⎣ 2πσ1

/ 2σ22

S1

=

1
e
2πσ1

∫

S1

⎡
μ σ2 + μ σ2
− ⎢ X − 2 12 12 2
σ1 + σ2
⎢⎣

=

2

2σ12σ22

−(μ1 −μ2 )2

σ12 + σ22

⋅ e 2(σ1 + σ2 ) dX

2

⎡
μ σ2 + μ σ2 ⎤
− ⎢ X − 2 12 12 2 ⎥
σ1 + σ2 ⎥⎦
⎢⎣
e

−(μ1 −μ2 )2

2
2
1
e 2(σ1 + σ2 )
2πσ1

⎤
⎥
⎥⎦

∫

⎤
⎥ dX
⎦

2

Var(Δ( X)) =

2

+

dX

(13)

−(μ1 −μ2 )2

2 2σ12 + σ22

2
2
e 2σ1 + σ2 +

−(μ1 −μ2 )2

σ1

−(μ1 −μ2 )2

2
2
2
2
1
e σ1 + 2σ2 − e σ1 + 2σ2
4
2 σ12 + 2σ22

Δ( X) which is given by d(S1,S2) = 1 - Δ( x) . By calculating

2

the mean and the variance of Δ(X) in formula (Δ1) and
(Δ2), the mean and the variance of the d-value are derived
straightforward as follows:

2

e 2(σ1 + σ2 )

σ12 + σ22

−(μ1 −μ2 )2

σ2

( Δ2 )

As illustrated in the beginning, d-value is a function of

−(μ1 −μ2 )2

σ2

=

−(μ1 −μ2 )2

−(μ1 −μ2 )2

S1

2
2
2σ12 σ22
1
e 2(σ1 + σ2 ) ⋅ π
2πσ1
σ12 + σ22

=

=

−(μ1 −μ2 )2

2
2
2
2
(1 − p)2 σ12
e σ1 + 2σ2 −
e σ1 + σ2
σ12 + σ22
σ12 + 2σ22

(1 − p)σ1

2σ12σ22
σ12 + σ22

−(μ1 −μ2 )2

2
2
2
2
p2 σ22
e 2σ1 + σ2 −
e σ1 + σ2
σ12 + σ22
2σ12 + σ22

pσ 2

Similarly,
2

/ 2σ12

E(e −( X −μ1 )

−(μ1 −μ2 )2

σ1

| S2 ) =

e

σ12 + σ22

2(σ12 + σ22 )

.

(14)

p

−(μ1 −μ2 )2

σ2

2

σ12 + σ22

σ1

2

e 2(σ1 + σ2 ) + (1 − p)

−(μ1 −μ2 )2
2

σ12 + σ22

−(μ1 −μ2 )2

σ1 + σ2

2

e 2(σ1 + σ2 ) =

2

2 σ12 + σ22

E(d(S1 , S2 )) = 1 − p

Var(d(S1 , S2 )) = (

By (12)–(14), the mean of Δ(X) when p = 0.5 is
2

e 2(σ1 + σ2 ) .

(Δ1)

(2). Calculation of the variance of Δ(X)
Since S1 and S2 are independent, the variance of Δ(X) is
given by

σ2

pσ 2
2σ12 + σ22

σ12 + σ22
−(μ1 −μ2 )2

e

2σ12 + σ22

−

e

−(μ1 −μ2 )2
2(σ12 + σ22 )

p2 σ22
σ12 + σ22

− (1 − p)

−(μ1 −μ2 )2

e

σ12 + σ22

σ1

+

(1 − p)σ1
σ12 + 2σ22

σ12 + σ22
−(μ1 −μ2 )2

e

σ12 + 2σ22

−

e

−(μ1 −μ2 )2
2(σ12 + σ22 )

(1 − p)2 σ12
σ12 + σ22

( 16 )

−(μ1 −μ2 )2

e

σ12 + 2σ22

) /(n1 + n2 )

( 17 )

For a large sample, by the central limit theorem, the distribution of the d-value follows a truncated normal distribution approximately: d(S1,S2)→ N(E(d),Var(d)) on a
restrained domain of [0 1].
For the purpose of further illustration, several special cases
of the distribution of d-value under application-specific
constrains are demonstrated.

( 15 )

Var(Δ( X)) = Var(IS1 ( X) fF(S2 )( X)) + Var(IS2 ( X) fF(S1 )( X)).

i. Balance study: p = 0.5, n1 = n2 = n/2

Var(IS1 ( X) fF(S2 )( X))
= E(IS1 ( X) fF2(S )( X)) − E2 (IS1 ( X) fF(S2 )( X))
2

= E(e

−( X −μ2 )2 / σ22

2

= p ∫ e −( X −μ2 )

/ σ22

S1

= p∫

S1

=

=

=

1
e
2πσ1

p
e
2πσ1
p
e
2πσ1

| S1 )P(S1 ) −

p2σ22
σ12 + σ22

e

−(μ1 −μ2 )2
σ12 + σ22

2
2
⎡ 1
e −( X −μ1 ) / 2σ1
⎢
⎣ 2πσ1

⎡
μ σ2 + μ σ2 / 2 ⎤
− ⎢ X − 2 12 12 2 ⎥
σ1 + σ2 / 2 ⎦⎥
⎢⎣

−(μ1 −μ2 )2
2σ12 + σ22

∫e

2

⎤
p2σ22
e
⎥ dX − 2
σ1 + σ22
⎦

σ12σ22
σ12 + σ22 / 2

⎡
μ σ2 + μ σ2 / 2 ⎤
− ⎢ X − 2 12 12 2 ⎥
σ1 + σ2 / 2 ⎥⎦
⎢⎣

E(d(S1 , S2 )) = 1 −

pσ2
2σ12 + σ22

e

⋅ 2π

−(μ1 −μ2 )2
2σ12 + σ22

−

σ12σ22
2σ12 + σ22
p2σ22
σ12 + σ22

e

−

2

2

−(μ1 −μ2 )
2

2

⋅ e 2(σ1 + σ2 / 2) dX −
σ12σ22
σ12 + σ22 / 2

dX −

S1
−(μ1 −μ2 )2
2σ12 + σ22

−(μ1 −μ2 )2
σ12 + σ22

p2σ22
σ12 + σ22

e

p2σ22
σ12 + σ22

p2σ22
σ12 + σ22

e

e

−(μ1 −μ2 )
σ12 + σ22

−(μ1 −μ2 )2
σ12 + σ22

σ2
2 2σ12 + σ22

E(d(S1 , S2 )) = 1 −

−(μ1 −μ2 )2
σ12 + σ22

Var(d(S1 , S2 )) = (

2

−(μ1 −μ2 )

2

−(μ1 −μ2 )

2
2
(1 − p)2 σ12 σ12 + σ22
e
.
e σ1 + 2σ2 −
σ12 + σ22
σ12 + 2σ22

(1 − p)σ1

2 σ12 + σ12

e

−(μ1 −μ2 )2
2σ12 + σ22

+

e

−(μ1 −μ2 )2
2(σ12 + σ22 )

σ1
2 σ12 + 2σ22

e

−(μ1 −μ2 )2
σ12 + 2σ22

1
− e
4

−(μ1 −μ2 )2
σ12 + σ22

)/ n

ii. Balance study with equal mean: p = 0.5, n1 = n2 = n/2, μ1
= μ2

−(μ1 −μ2 )2
σ12 + σ22

Similarly,

Var(IS2 ( X) fF(S1 )( X)) =

Var(d(S1 , S2 )) = (

σ1 + σ2

σ1 + σ2
2 σ12 + σ22
σ2
2 2σ12 + σ22

+

σ1
2 σ12 + 2σ22

1
− )/n
4

iii. Balance study with equal variance: p = 0.5, n1 = n2, σ12
= σ2 2 = σ2
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test based on the asymptotic distribution obtained from
section I.

2

E(d(S1 , S2 )) = 1 −

1
e
2

−(μ1 −μ2 )
4σ 2

2

2

Var(d(S1 , S2 )) = (

1
e
3

−(μ1 −μ2 )
3σ2

−

1
e
4

−(μ1 −μ2 )
2σ2

)/ n

iv. Balance study with equal variance of 1 and large samples:σ2= 1, n1 = n2 ≥ 25
1 −(μ1 −μ2 )2 / 4
E(d(S1 , S2 )) = 1 −
e
2
1 −(μ1 −μ2 )2 / 3 1 −(μ1 −μ2 )2 / 2
)/n
Var(d(S1 , S2 )) = (
e
− e
4
3

The null hypothesis of the test is H0:μ1 = μ2, where μ1 and
μ2 are the mean gene expression levels of two studied
groups. According to the asymptotic distribution of the dvalue, following its special case (ii) (balance study with
equal mean), a test statistic under the null hypothesis for
large sample size (n >= 25) is given by

z0 =

d − E(d)H0

E(d(S1 , S2 )) = 1 −

Where

1 −(μ1 −μ2 )2 / 4 1 −(μ1 −μ2 )2 / 3 1 −(μ1 −μ2 )2 / 2
⎛
⎞
d(S1 , S2 ) → N ⎜ 1 −
e
,(
e
− e
)/n ⎟
4
2
3
⎝
⎠

v. Balance study with equal variance of 1 and equal mean
for large samples:σ2 = 1, μ1 = μ2, n1 = n2 ≥ 25
E(d(s1,s2)) = 1-

1 1
1
≈ 0.293, var(d(s1,s2))=(
, )/n ≈
3 4
2

( 18 )

~ N(0,1).

var(d)

Var(d(S1 , S2 )) = (

σ2
2 2σ12 + σ22

+

σ1 + σ2

and

2 σ12 + σ22
σ1
2 σ12 + 2σ22

1
− ) / n. .
4

Suppose dobs is an observed d-value for a given study based
on two independent samples S1 = {xi,i = 1,...,n1} and S2 =

0.327/n

{yi,i = 1,...,n2}. The population variances σ12 and σ22 are

d(S1,S2) → N(0.293,0.327/n) with a restrained domain of
[0 1].

estimated by the corresponding sample variances

Figure 7 shows the density function of d-value for this special case when n = 50 with mean 0.293 and variance 0.08.
Calculation of p-value
P-value is also called the observed level of significance and
is commonly used to report the smallest α-level at which
the observed test result is significant. In this section, we
derived the parametric calculation of p-value for the FM

s12 =

1
n1 − 1

n1

∑ (xi − x )2
i =1

1
n2 − 1

and s22 =

n2

∑ (yi − y )2

.

i =1

Thus the mean and variance of d-value are estimated by

μˆ d = Eˆ (d) = 1 −
m d) = (
σˆ 2d = var(

s1 + s2

and

2 s12 + s12
s2
2

2s12

+

s22

s1

+
2

s12

+

2s22

1
− )/n
4

P-value is therefore derived as follows:
P − value = P{d ≥ dobs | μ1 = μ2}
d − μ d dobs − μ d
≈ P{Z =
≥
| μ1 = μ2}
σd
σd

( Δ3 )

d − μd
≈ P{Z ≥ obs
}
σd
d − μd
= 1 − Φ( obs
)
σd

Figure
Asymptotic
with
equal
7 variance
density function
of one of d-value for a balance study
Asymptotic density function of d-value for a balance study
with equal variance of one.

Application in Gene Expression Analysis
Table 4 shows the calculated P-values for the study example. It is concluded that the p-values calculated by (Δ3) are
consistent with the empirical p-values listed in Table 1
except the Gene 5 which is above 0.05. As a reminder,
while the formula (Δ3) is being applied for the calculation
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Table 4: P-values given by FM-test for five genes from the study example.
Gene ID

IR

IS

d-value

p-value
FM-test by(Δ 3)

1
2
3
4
5

750
123
246
200
598

559
142
213
191
424

649
11
232
220
695

685
406
134
83
451

636
220
67
197
141

310
305
86
49
342

359
398
79
81
260

135
707
77
116
266

of p-values, a large sample size (n >= 25) is desired for a
robust estimation due to the assumption of the CLT.

97
905
94
111
229

178
688
61
135
234
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